On April 3, 2024, Dr. Worapol Ngamcherdtrakul (COO) took the stage at the MedInvest Biotech & Pharma Investor Conference in NYC. It was an exciting opportunity to showcase our groundbreaking patented drug delivery platform, PDX-NP™. Developed as an alternative to lipid nanoparticles (LNPs) that primarily home to the liver, our non-lipid PDX-NP™ can load multiple cargo types simultaneously and target both cancer and immune cells in tissues beyond the liver, revolutionizing the landscape of targeted therapy and immunotherapy for cancer. Our lead therapeutic candidate, ARAC-02™, not only kills cancer cells, but also stimulates an anti-tumor immune response, providing more effective and durable tumor control in preclinical models. We are proud of the exciting advancements our team is making! It was also inspiring to hear from and connect with the investment community and other biotech companies, whose missions are to revolutionize healthcare.
See a recording of Dr. Ngamcherdtrakul’s talk: